NextCure Inc (NXTC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $29.31M
Last updated: Nov 17, 2026 at 11:05 AM ET
NextCure Inc (NXTC) Earnings: Report Dates and Results
NextCure (NXTC) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, NextCure reported EPS of -$1.67, below the -$0.90 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NXTC has an expected report date of Mar 3, 2027.
Earnings History
Of the 31 quarters below that had an estimate, NXTC beat 16 and missed 15. The widest gap in the table came in the quarter ended Mar 31, 2019, when EPS landed 741.51% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.67 | -$0.90 | -$0.90 - -$0.90 | -85.56% | Miss | N/A | 1 | 0 up, 0 down | Nov 10, 2026 | N/A |
| Jun 30, 2026 | -$1.84 | -$1.98 | -$2.03 - -$1.84 | +7.07% | Beat | N/A | 4 | 0 up, 0 down | Aug 6, 2026 | N/A |
| Mar 31, 2026 | -$1.87 | -$2.03 | -$2.40 - -$1.81 | +7.88% | Beat | N/A | 3 | 2 up, 0 down | May 7, 2026 | N/A |
| Dec 31, 2025 | -$0.81 | -$2.29 | -$2.38 - -$2.14 | +64.63% | Beat | N/A | 3 | 3 up, 0 down | Mar 5, 2026 | N/A |
| Sep 30, 2025 | -$3.22 | -$4.06 | -$4.47 - -$3.65 | +20.69% | Beat | N/A | 3 | 1 up, 0 down | Nov 5, 2025 | N/A |
| Jun 30, 2025 | -$11.29 | -$4.62 | -$4.68 - -$4.55 | -144.37% | Miss | N/A | 2 | 1 up, 0 down | Aug 7, 2025 | N/A |
| Mar 31, 2025 | -$4.68 | -$4.80 | -$5.04 - -$4.56 | +2.50% | Beat | N/A | 2 | 0 up, 1 down | May 1, 2025 | N/A |
| Dec 31, 2024 | -$0.41 | -$0.36 | -$0.36 - -$0.36 | -13.89% | Miss | N/A | 1 | 0 up, 1 down | Mar 6, 2025 | $3.28M |
| Sep 30, 2024 | -$4.92 | -$3.84 | -$4.44 - -$3.84 | -28.13% | Miss | N/A | 2 | 0 up, 0 down | Nov 7, 2024 | N/A |
| Jun 30, 2024 | -$6.60 | -$4.95 | N/A | -33.33% | Miss | N/A | 3 | 0 up, 0 down | Aug 1, 2024 | N/A |
| Mar 31, 2024 | -$6.26 | -$5.52 | -$6.12 - -$5.16 | -13.41% | Miss | N/A | 4 | 0 up, 0 down | May 2, 2024 | N/A |
| Dec 31, 2023 | -$0.52 | -$0.54 | -$0.59 - -$0.48 | +3.70% | Beat | N/A | 4 | 0 up, 0 down | Mar 21, 2024 | $6.28M |
| Sep 30, 2023 | -$6.12 | -$7.84 | -$8.16 - -$7.56 | +21.94% | Beat | N/A | 4 | 0 up, 0 down | Nov 2, 2023 | N/A |
| Jun 30, 2023 | -$7.68 | -$7.20 | -$7.20 - -$6.84 | -6.67% | Miss | N/A | 3 | 0 up, 0 down | Aug 3, 2023 | N/A |
| Mar 31, 2023 | -$6.96 | -$7.44 | -$8.40 - -$7.08 | +6.45% | Beat | N/A | 4 | 0 up, 0 down | May 4, 2023 | N/A |
| Dec 31, 2022 | -$0.62 | -$0.66 | -$0.76 - -$0.59 | +6.06% | Beat | N/A | 6 | 0 up, 0 down | Mar 2, 2023 | N/A |
| Sep 30, 2022 | -$8.16 | -$7.80 | -$8.76 - -$5.04 | -4.62% | Miss | N/A | 7 | 0 up, 0 down | Nov 3, 2022 | N/A |
| Jun 30, 2022 | -$7.80 | -$9.02 | -$9.36 - -$7.68 | +13.53% | Beat | N/A | 6 | 0 up, 0 down | Aug 4, 2022 | N/A |
| Mar 31, 2022 | -$8.88 | -$8.02 | -$8.28 - -$7.68 | -10.72% | Miss | N/A | 6 | 0 up, 0 down | May 5, 2022 | N/A |
| Dec 31, 2021 | -$0.61 | -$0.67 | -$0.74 - -$0.54 | +8.96% | Beat | N/A | 8 | N/A | Mar 3, 2022 | N/A |
| Sep 30, 2021 | -$7.80 | -$7.97 | -$8.40 - -$7.68 | +2.13% | Beat | N/A | 9 | N/A | Nov 4, 2021 | N/A |
| Jun 30, 2021 | -$7.80 | -$7.44 | -$7.80 - -$6.72 | -4.84% | Miss | N/A | 7 | N/A | Aug 5, 2021 | N/A |
| Mar 31, 2021 | -$7.20 | -$7.15 | -$8.16 - -$6.48 | -0.70% | Miss | -2281.8% | 6 | N/A | May 6, 2021 | N/A |
| Dec 31, 2020 | -$0.54 | -$0.60 | -$0.66 - -$0.50 | +10.00% | Beat | N/A | 9 | N/A | Mar 4, 2021 | N/A |
| Sep 30, 2020 | -$7.08 | -$6.52 | -$8.64 - -$5.28 | -8.59% | Miss | N/A | 8 | N/A | Nov 5, 2020 | N/A |
| Jun 30, 2020 | -$6.36 | -$5.82 | -$7.56 - -$4.20 | -9.28% | Miss | N/A | 9 | N/A | Aug 6, 2020 | N/A |
| Mar 31, 2020 | $0.33 | -$0.44 | -$1.31 - $0.23 | +175.00% | Beat | N/A | 7 | N/A | May 7, 2020 | $22.38M |
| Dec 31, 2019 | -$4.08 | -$8.46 | -$12.85 - -$3.60 | +51.77% | Beat | N/A | 7 | N/A | Mar 12, 2020 | $2.00M |
| Sep 30, 2019 | -$4.44 | -$4.08 | -$4.32 - -$4.08 | -8.82% | Miss | N/A | 2 | N/A | Nov 12, 2019 | $1.58M |
| Jun 30, 2019 | -$7.32 | -$7.56 | -$7.56 - -$3.60 | +3.17% | Beat | N/A | 2 | N/A | Aug 12, 2019 | $1.40M |
| Mar 31, 2019 | -$4.46 | -$0.53 | N/A | -741.51% | Miss | N/A | N/A | N/A | Jun 10, 2019 | $1.36M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$20.00, after -$18.19 the year before. It was -$20.30 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$20.00 | N/A |
| Dec 31, 2024 | -$18.19 | N/A |
| Dec 31, 2023 | -$21.28 | N/A |
| Dec 31, 2022 | -$25.46 | N/A |
| Dec 31, 2021 | -$23.41 | N/A |
| Dec 31, 2020 | -$13.65 | N/A |
| Dec 31, 2019 | -$20.30 | N/A |
Frequently Asked Questions About NXTC
When is NextCure's next earnings date?
NextCure's next earnings report is expected for Mar 3, 2027.
Did NXTC beat earnings estimates last quarter?
No. NextCure reported EPS of -$1.67 for the quarter ended Sep 30, 2026, below the -$0.90 estimate by 85.56%.
What EPS do analysts expect from NXTC next quarter?
The consensus EPS estimate for NextCure for the quarter ending Dec 31, 2026 is -$1.44 from 4 analysts, with estimates from -$1.98 to -$0.83.
How often does NXTC beat earnings estimates?
NextCure beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of -17.63%.
NXTC pages: Overview, Earnings, Forecast, Financials, Competitors